Charles Schwab’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $66.8M | Sell |
395,118
-7,582
| -2% | -$1.31M | 0.01% | 963 |
|
|
2025
Q4 | $73.5M | Buy |
402,700
+20,653
| +5% | +$2.88M | 0.01% | 896 |
|
|
2025
Q3 | $46.4M | Buy |
382,047
+25,396
| +7% | +$2.86M | 0.01% | 1203 |
|
|
2025
Q2 | $37.2M | Buy |
356,651
+19,405
| +6% | +$2.05M | 0.01% | 1279 |
|
|
2025
Q1 | $39.3M | Buy |
337,246
+9,212
| +3% | +$1.05M | 0.01% | 1231 |
|
|
2024
Q4 | $27.8M | Buy |
328,034
+5,438
| +2% | +$500K | 0.01% | 1509 |
|
|
2024
Q3 | $29M | Buy |
322,596
+12,778
| +4% | +$1.12M | 0.01% | 1480 |
|
|
2024
Q2 | $24.9M | Buy |
309,818
+8,744
| +3% | +$647K | ﹤0.01% | 1527 |
|
|
2024
Q1 | $24M | Buy |
301,074
+5,373
| +2% | +$451K | 0.01% | 1505 |
|
|
2023
Q4 | $23.5M | Buy |
295,701
+5,830
| +2% | +$390K | 0.01% | 1487 |
|
|
2023
Q3 | $20.3M | Buy |
289,871
+21,457
| +8% | +$1.6M | 0.01% | 1505 |
|
|
2023
Q2 | $19.3M | Buy |
268,414
+19,296
| +8% | +$1.42M | 0.01% | 1531 |
|
|
2023
Q1 | $15.4M | Sell |
249,118
-652
| -0.3% | -$42.8K | ﹤0.01% | 1651 |
|
|
2022
Q4 | $19.3M | Buy |
249,770
+23,417
| +10% | +$1.4M | 0.01% | 1474 |
|
|
2022
Q3 | $10.1M | Buy |
226,353
+12,067
| +6% | +$603K | ﹤0.01% | 1822 |
|
|
2022
Q2 | $8.21M | Buy |
214,286
+1,073
| +0.5% | +$33.9K | ﹤0.01% | 1939 |
|
|
2022
Q1 | $8.82M | Buy |
213,213
+5,983
| +3% | +$185K | ﹤0.01% | 2021 |
|
|
2021
Q4 | $7.83M | Buy |
207,230
+3,178
| +2% | +$117K | ﹤0.01% | 2131 |
|
|
2021
Q3 | $6.73M | Buy |
204,052
+17,957
| +10% | +$700K | ﹤0.01% | 2233 |
|
|
2021
Q2 | $12.6M | Buy |
186,095
+3,253
| +2% | +$195K | ﹤0.01% | 1883 |
|
|
2021
Q1 | $10.4M | Buy |
182,842
+5,575
| +3% | +$392K | ﹤0.01% | 1947 |
|
|
2020
Q4 | $14.4M | Buy |
177,267
+1,854
| +1% | +$139K | 0.01% | 1630 |
|
|
2020
Q3 | $12.5M | Sell |
175,413
-5,627
| -3% | -$438K | 0.01% | 1534 |
|
|
2020
Q2 | $14.9M | Buy |
181,040
+13,210
| +8% | +$1.02M | 0.01% | 1381 |
|
|
2020
Q1 | $9.87M | Buy |
167,830
+7,652
| +5% | +$623K | 0.01% | 1455 |
|
|
2019
Q4 | $16.6M | Buy |
160,178
+7,667
| +5% | +$310K | 0.01% | 1350 |
|
|
2019
Q3 | $3.09M | Buy |
152,511
+95,814
| +169% | +$2.46M | ﹤0.01% | 2216 |
|
|
2019
Q2 | $1.46M | Buy |
+56,697
| New | +$1.14M | ﹤0.01% | 2465 |
|
|
2017
Q2 | – | Sell |
-17,700
| Closed | -$70K | – | 3106 |
|
|
2017
Q1 | $70K | Hold |
17,700
| – | – | ﹤0.01% | 3033 |
|
|
2016
Q4 | $120K | Hold |
17,700
| – | – | ﹤0.01% | 3030 |
|
|
2016
Q3 | $140K | Hold |
17,700
| – | – | ﹤0.01% | 2982 |
|
|
2016
Q2 | $134K | Buy |
+17,700
| New | +$163K | ﹤0.01% | 3027 |
|
Other funds holding AXSM
VPM
VCM
DTC
Charles Schwab's AXSM Position: Q1 2026 in Review
Charles Schwab reduced its Axsome Therapeutics (AXSM) stake by 1.9% in Q1 2026, selling an estimated $1.31M and leaving 395,118 shares worth $66.8M. The position accounts for 0.01% of the portfolio, ranked #963.
Charles Schwab first reported a position in AXSM in Q2 2016 and has held it in 32 quarters since. The position peaked at $73.5M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Charles Schwab held 395,118 shares of Axsome Therapeutics worth $66.8M as of Q1 2026.
- Charles Schwab sold 7,582 Axsome Therapeutics shares in Q1 2026, an estimated $1.31M.
- Axsome Therapeutics made up 0.01% of Charles Schwab's portfolio in Q1 2026, its #963 holding.
- Charles Schwab first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 32 quarters since.
- Charles Schwab's Axsome Therapeutics position peaked at $73.5M in Q4 2025.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.